Shares of Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) saw unusually-high trading volume on Wednesday . Approximately 1,213,998 shares changed hands during mid-day trading, an increase of 291% from the previous session’s volume of 310,170 shares.The stock last traded at $0.19 and had previously closed at $0.17.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last announced its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The business had revenue of $0.54 million for the quarter. Navidea Biopharmaceuticals had a negative return on equity of 38.60% and a negative net margin of 688.85%.

Navidea Biopharmaceuticals Company Profile (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

See Also: Earnings Per Share (EPS) Explained

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.